VIVOS INC
Vivos develops yttrium-90-based precision radionuclide therapy devices for cancer treatment in people and animals. Its RadioGel product is for human therapy, while IsoPet is marketed for veterinary use. The injectable gel contains yttrium-90 particles intended to deliver radiation within tumors. Vivos also sells PLGA-g-PEG polymers and PrecisionGel, a hydrogel platform for delivering active pharmaceutical ingredients and therapeutic agents. The company’s animal therapy business includes selling IsoPet and related services, as well as certifying veterinary clinics to administer treatments. It also sells PrecisionGel polymer through Akina, Inc. Vivos is headquartered in Kennewick, Washington. Its human therapy product is in development, while IsoPet is commercially distributed for animal therapy. The company is also developing applications for its technologies beyond cancer treatment and has established Vivos Scientific India LLP to support clinical and manufacturing activities in India.
No SEC Form 4 filings for $RDGL in the last 30 days.
See all $RDGL insider activity →Vivos Inc. (RDGL) plans to expand its IsoPet Animal Cancer Division with four new U.S. veterinary clinics in Kentucky, North Carolina, California, and Florida. The company expects this to increase treatment capacity and revenue once regulatory and operational requirements are met. IsoPet uses Yttrium-90 for targeted radiation therapy in animals with cancer.
VIVOS INC (RDGL) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On October 7, 2026, the Company entered into a Stock Purchase and Exchange Agreement (the “ Exchange Agreement ”), with a member of its Board of Directors (the “ Director ”). Pursuant to the Exchange Agreement, the Director ag
Korenko Michael K (CEO) purchased 200,000 shares of VIVOS INC (RDGL) at $0.50 on 2026-09-30.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning RDGL (VIVOS INC). Coverage has been balanced: 0 bullish, 2 neutral, and 0 bearish.
Recent RDGL coverage spans insider activity, financial news and corporate actions.
Incremental network expansion could support future IsoPet treatment volumes and recurring product demand, but near-term revenue timing is uncertain.
The transaction dilutes existing shareholders and adds preferred equity, likely exerting modest downward pressure on the stock.
Insider buying by the CEO may signal confidence and could provide modest upward pressure on the stock.
Small insider purchase signals confidence but limited market impact due to low dollar amount.
This is a small insider open-market buy with limited signal value, but it is a fresh, timestamped datapoint for RDGL.
AlphAI scores every news story that mentions RDGL with an AI model for sentiment and relevance, and aggregates insider trades from VIVOS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Vivos Inc. (RDGL) plans to expand its IsoPet Animal Cancer Division with four new U.S. veterinary clinics in Kentucky, North Carolina, California, and Florida. The company expects this to increase treatment capacity and revenue once regulatory and operational requirements are met. IsoPet uses Yttrium-90 for targeted radiation therapy in animals with cancer.
5 min readVIVOS INC (RDGL) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On October 7, 2026, the Company entered into a Stock Purchase and Exchange Agreement (the “ Exchange Agreement ”), with a member of its Board of Directors (the “ Director ”). Pursuant to the Exchange Agreement, the Director ag
1 min readKorenko Michael K (CEO) purchased 200,000 shares of VIVOS INC (RDGL) at $0.50 on 2026-09-30.
1 min readWeeks Brad Allan (President) purchased 25,550 shares of VIVOS INC (RDGL) at $0.05 on 2026-09-16.
1 min readWeeks Brad Allan (President) purchased 50,000 shares of VIVOS INC (RDGL) at $0.05 on 2026-08-10.
2 min readKorenko Michael K (CEO AND PRESIDENT) purchased 150,000 shares of VIVOS INC (RDGL) at $0.05 on 2026-08-10.
1 min readWeeks Brad Allan (President) purchased 92,000 shares of VIVOS INC (RDGL) at $0.05 across 2 trades over 2026-07-21 to 2026-07-22.
1 min readKorenko Michael K (CEO AND PRESIDENT) purchased 200,000 shares of VIVOS INC (RDGL) at $0.06 on 2026-07-15.
1 min readWeeks Brad Allan (President) purchased 60,000 shares of VIVOS INC (RDGL) at $0.08 across 2 trades over 2026-07-09 to 2026-07-10.
2 min readIn what could prove to be a transformational development in cancer treatment, Vivos Inc. RDGL, the maker of the RadioGel® Precision Radionuclide Therapy™, has reported positive results from its first-ever human trial.
3 min read
